Pfizer Inc. (PFE) Position Lifted by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 742.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,470 shares of the biopharmaceutical company’s stock after buying an additional 10,990 shares during the period. Hillsdale Investment Management Inc.’s holdings in Pfizer were worth $445,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the stock. Probity Advisors Inc. increased its holdings in shares of Pfizer by 4.6% during the 2nd quarter. Probity Advisors Inc. now owns 38,823 shares of the biopharmaceutical company’s stock valued at $1,304,000 after acquiring an additional 1,697 shares during the last quarter. Sanders Capital LLC increased its holdings in shares of Pfizer by 10.8% during the 2nd quarter. Sanders Capital LLC now owns 16,933,077 shares of the biopharmaceutical company’s stock valued at $626,222,000 after acquiring an additional 1,644,036 shares during the last quarter. American Trust Investment Advisors LLC increased its holdings in shares of Pfizer by 6.6% during the 2nd quarter. American Trust Investment Advisors LLC now owns 6,425 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 400 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Pfizer by 1.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 36,985 shares of the biopharmaceutical company’s stock valued at $1,243,000 after acquiring an additional 616 shares during the last quarter. Finally, Country Trust Bank increased its holdings in shares of Pfizer by 0.5% during the 2nd quarter. Country Trust Bank now owns 806,756 shares of the biopharmaceutical company’s stock valued at $27,099,000 after acquiring an additional 3,882 shares during the last quarter. 70.06% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.

Shares of Pfizer Inc. (NYSE PFE) opened at $35.71 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a 52-week low of $31.67 and a 52-week high of $39.43. The company has a market capitalization of $212,860.00, a P/E ratio of 10.14, a price-to-earnings-growth ratio of 1.97 and a beta of 0.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter last year, the company earned $0.47 EPS. The company’s quarterly revenue was up .6% on a year-over-year basis. sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer declared that its Board of Directors has initiated a share buyback program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be given a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.81%. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is currently 38.64%.

PFE has been the topic of a number of analyst reports. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a report on Tuesday, October 31st. JPMorgan Chase & Co. set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. UBS Group set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. Deutsche Bank set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. Finally, Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price objective on the stock in a report on Thursday, November 23rd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and an average price target of $39.45.

COPYRIGHT VIOLATION NOTICE: “Pfizer Inc. (PFE) Position Lifted by Hillsdale Investment Management Inc.” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/16/pfizer-inc-pfe-position-lifted-by-hillsdale-investment-management-inc.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply